Drug Profile
M 254
Alternative Names: hsIgG; Hypersialylated IgG; Hypersialylated immunoglobulin; M254Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Virdante Pharmaceuticals
- Developer Momenta Pharmaceuticals
- Class Anti-inflammatories; Immunoglobulin isotypes; Immunotherapies; Recombinant proteins; Sialic acids
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Idiopathic thrombocytopenic purpura
- No development reported Chronic inflammatory demyelinating polyradiculoneuropathy
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Chronic inflammatory demyelinating polyradiculoneuropathy in USA (Parenteral)
- 01 Jun 2022 Takeda in-licenses M 254 from Momenta Pharmaceuticals
- 02 Aug 2021 Momenta Pharmaceuticals terminates a phase I/II trial in Idiopathic thrombocytopenic purpura in Belgium, Hungary, Italy, Netherlands, Poland, Spain, USA, based on sponsor decision (IV) after December 2018 (NCT03866577) (EudraCT2018-003534-32)